Basit öğe kaydını göster

dc.contributor.authorKalkanlı, Arif
dc.contributor.authorSönmez, Salih Zeki
dc.contributor.authorGüvel, Mine
dc.contributor.authorAğlamış, Erdoğan
dc.contributor.authorAraz, Şeyhmuz
dc.contributor.authorAsfuroğlu, Ahmet
dc.contributor.authorAvcı, Hüseyin Kürşad
dc.contributor.authorAydın, Memduh
dc.contributor.authorAydos, Murat
dc.contributor.authorYazar, Selim
dc.date.accessioned2023-10-09T12:47:26Z
dc.date.available2023-10-09T12:47:26Z
dc.date.issued2023en_US
dc.identifier.citationKalkanlı, A., Sönmez, S. Z., Güvel, M., Ağlamış, E., Araz, Ş., Asfuroğlu, A. ... Yazar, S. (2023). Management of priapism: Results of a nationwide survey and comparison with international guidelines. Urology Research and Practice, 49(4), 225-232. https://doi.org/10.5152/tud.2023.22209en_US
dc.identifier.issn2980-1478
dc.identifier.urihttps://doi.org/10.5152/tud.2023.22209
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11540
dc.description.abstractObjective: The aim of this study is to evaluate current urologic practice regarding the management of priapism in Turkey and compare with international guidelines. Methods: Urologists and urology residents were invited to an online survey consisting of 30 multiple-choice questions on priapism-related clinical practices that were considered most important and relevant to practices by using Google Forms. Results: Total number of responses was 340. Respondents reported that they recorded a detailed patient’s medical history and physical examination findings (n = 340, 100%) and laboratory testing, which includes corporal blood gas analysis (n = 323, 95%). Participants announced that they performed Doppler ultrasound for 1/4 cases (n = 106, 31%), but 22% of the participants (n = 75) replied that they performed in >75% of cases. Participants (n = 311, 91%) responded that the first-line treatment of ischemic priapism is decompression of the corpus cavernosum. Moreover, most respondents (n = 320, 94%) stated that sympathomimetic injection drugs should be applied as the second step. About three-quarters of respondents (n = 247, 73%) indicated adrenaline as their drug of choice. Phosphodiesterase type 5 inhibitors seems to be the most preferred drug for stuttering priapism (n = 141, 41%). Participants (n = 284, 84%) replied that corpora-glanular shunts should be preferred as the first. A large number of participants (n = 239, 70%) declared that magnetic resonance imaging can be performed in cases with delayed (>24 hours) priapism to diagnose corporal necrosis. Most of the participants (84%) responded that penile prosthesis should be preferred to shunts in cases with delayed (>48 hours) priapism. Conclusion: It would be appropriate to improve the training offered by professional associations and to give more training time to the management of priapism during residency.en_US
dc.language.isoengen_US
dc.publisherAVESen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectAnd Rologyen_US
dc.subjectPenile Prosthesisen_US
dc.subjectPriapismen_US
dc.titleManagement of priapism: Results of a nationwide survey and comparison with international guidelinesen_US
dc.typearticleen_US
dc.relation.ispartofUrology Research and Practiceen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalıen_US
dc.authorid0000-0002-9976-9666en_US
dc.authorid0000-0002-5158-5630en_US
dc.identifier.volume49en_US
dc.identifier.issue4en_US
dc.identifier.startpage225en_US
dc.identifier.endpage232en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.5152/tud.2023.22209en_US
dc.institutionauthorÇalık, Gökhan
dc.institutionauthorTahra, Ahmet
dc.identifier.wos001056098400002en_US
dc.identifier.scopus2-s2.0-85172092241en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess